Search Results - "Brunsvig PF"

Gut Microbiota-Immune Interactions in Endometrial Cancer: Causal Mediation and Subtype-Specific Mechanisms.

Authors: Yu, Shuyang Shu, Wan Zhang, Jiarui et al.

Source: International Journal of Women's Health. Mar2026, Vol. 19, p1-22. 22p.

Disease control in patients with non‐small cell lung cancer using pemetrexed: Investigating the best treatment strategy.

Authors: Takahara, Yutaka Abe, Ryudai Sumito, Nagae et al.

Source: Thoracic Cancer. 4/22/2024, Vol. 15 Issue 12, p987-993. 7p.

Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial.

Authors: Aamdal E Inderberg EM Ellingsen EB et al.

Source: Frontiers in immunology [Front Immunol] 2021 May 11; Vol. 12, pp. 663865. Date of Electronic Publication: 2021 May 11 (Print Publication: 2021).

Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.

Authors: Brunsvig PF Guren TK Nyakas M et al.

Source: Frontiers in immunology [Front Immunol] 2020 Nov 26; Vol. 11, pp. 572172. Date of Electronic Publication: 2020 Nov 26 (Print Publication: 2020).

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

Design, synthesis, and evaluation of A therapeutic vaccine candidate against lung cancer based on multi-epitopes of MAGE-A3, TGF-β2, and VEGF-A.

Authors: Mokhtari, Vida Hashemi, Mehrdad Marandi, Sayeh Jafari et al.

Source: BMC Cancer. 10/22/2025, Vol. 25 Issue 1, p1-26. 26p.

Telomere–metabolism–immunity axis in sarcoma: Immune evasion mechanisms and therapeutic strategies.

Authors: Sung, Ji‐Yong Kim, June Hyuk

Source: Clinical & Translational Medicine. Oct2025, Vol. 15 Issue 10, p1-23. 23p.

Metal nanoparticles as a promising therapeutic approach for prostate cancer diagnosis and therapy: a comprehensive review.

Authors: Saadh MJ Khidr WA Alfarttoosi KH et al.

Source: Medical oncology (Northwood, London, England) [Med Oncol] 2025 Feb 23; Vol. 42 (4), pp. 83. Date of Electronic Publication: 2025 Feb 23.

Publication Type: Journal Article; Review

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 9435512 Publication Model: Electronic Cited Medium: Internet ISSN: 1559-131X (Electronic) Linking ISSN: 13570560 NLM ISO Abbreviation: Med Oncol Subsets: MEDLINE

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.

Authors: Chan, Stephen L. Schuler, Martin Kang, Yoon-Koo et al.

Source: Journal of Experimental & Clinical Cancer Research (17569966). 6/2/2022, Vol. 41 Issue 1, p1-19. 19p.

Towards personalized prostate cancer treatment with docetaxel in indonesia: a pharmacogenomics perspective.

Authors: Malau, Jekmal Rohmah, Siti Meilani, Nanda Diva et al.

Source: Egyptian Journal of Medical Human Genetics. 4/7/2025, Vol. 26 Issue 1, p1-22. 22p.

Canonical and non-canonical functions of the non-coding RNA component (TERC) of telomerase complex.

Authors: Cao, Chongwen Gong, Weiyi Shuai, Yuanlong et al.

Source: Cell & Bioscience. 3/1/2025, Vol. 15 Issue 1, p1-17. 17p.

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials.

Authors: Ellingsen EB Aamdal E Guren T et al.

Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 May; Vol. 10 (5).

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics.

Authors: Shou, Songting Maolan, Ayidana Zhang, Di et al.

Source: Experimental Hematology & Oncology. 1/27/2025, Vol. 14 Issue 1, p1-47. 47p.

Telomerase-based vaccines: a promising frontier in cancer immunotherapy.

Authors: Vahidi, Sogand Zabeti Touchaei, Arefeh

Source: Cancer Cell International. 12/20/2024, Vol. 24 Issue 1, p1-17. 17p.

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.

Authors: Ellingsen, Espen Basmo Bounova, Gergana Kerzeli, Iliana et al.

Source: Journal of Translational Medicine. 9/11/2022, Vol. 20 Issue 1, p1-13. 13p.

Telomerase in cancer- ongoing quest and future discoveries.

Authors: Mishra A Patel TN

Source: Molecular biology reports [Mol Biol Rep] 2025 Jan 25; Vol. 52 (1), pp. 161. Date of Electronic Publication: 2025 Jan 25.

Publication Type: Journal Article; Review

Journal Info: Publisher: Reidel Country of Publication: Netherlands NLM ID: 0403234 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-4978 (Electronic) Linking ISSN: 03014851 NLM ISO Abbreviation: Mol Biol Rep Subsets: MEDLINE

Vaccine-based therapeutic interventions in lung cancer management: A recent perspective.

Authors: Gupta DS Abjani NK Dave Y et al.

Source: Medical oncology (Northwood, London, England) [Med Oncol] 2024 Sep 24; Vol. 41 (11), pp. 249. Date of Electronic Publication: 2024 Sep 24.

Publication Type: Journal Article; Review

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 9435512 Publication Model: Electronic Cited Medium: Internet ISSN: 1559-131X (Electronic) Linking ISSN: 13570560 NLM ISO Abbreviation: Med Oncol Subsets: MEDLINE

NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.

Authors: Haakensen, Vilde Drageset Nowak, Anna K. Ellingsen, Espen Basmo et al.

Source: Journal of Translational Medicine. 5/31/2021, Vol. 19 Issue 1, p1-9. 9p.

High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study.

Authors: Sumiyoshi, Issei Okabe, Takahiro Togo, Shinsaku et al.

Source: Journal of Translational Medicine. 2/27/2021, Vol. 19 Issue 1, p1-11. 11p.

Regulation of telomerase towards tumor therapy.

Authors: Yan, Siyu Lin, Song Qiu, Hongxin et al.

Source: Cell & Bioscience. 12/18/2023, Vol. 13 Issue 1, p1-10. 10p.

Combining old and new concepts in targeting telomerase for cancer therapy: transient, immediate, complete and combinatory attack (TICCA).

Authors: Ali, Jaber Haj Walter, Michael

Source: Cancer Cell International. 9/26/2023, Vol. 23 Issue 1, p1-24. 24p.